Policy Issues in Nanotechnology and Oncology: A Workshop

When: July 12, 2010 - July 13, 2010 (8:00 AM Eastern)

Topics Biomedical and Health Research, Diseases, Health Care Workforce, Health Services, Coverage, and Access, Quality and Patient Safety
Activity: National Cancer Policy Forum
Board: Board on Health Care Services

Public investment in nanotechnology for medicine continues to increase, and medical products based on nanotechnology are on the market. Several of the first FDA-approved uses of nanotechnology in medicine were for new formulations of standard chemotherapeutic agents to enhance delivery of the drugs to cancer cells. Nanotechnology has also been used to improve contrast materials for imaging. Nanotechnology holds promise for diagnostic tools and combination products such as theranostics. A great deal of research funding is currently being devoted to research in nanomedicine, providing ample opportunity for scientific advances and new products. Even so, there are substantial challenges to overcoming clinical research and translational science hurdles.

The goal of the workshop was to address what nanomedicine is, what it can do, its potential risks and benefits, and the state of the art for standards and regulation, all with respect to nanomedicine in oncology. The primary audiences were clinical researchers, clinicians, policy makers, and the public. The end product of the workshop included a workshop summary published by the National Academies Press to both educate the intended audience on the issues relevant to nanotechnology in oncology and provide an objective and scientifically grounded summary of perspectives about how this audience can contribute to the field.

Upcoming Meetings for this Activity

Previous Meetings for this Activity

Also of Interest